Hologic posts slight Q4 revenue decrease

By LabPulse.com staff writers

November 2, 2021 -- Hologic posted a slight decrease in revenue for the company's fourth quarter, which it attributed to lower demand for its SARS-CoV-2 assays compared with the same period in 2020.

For the quarter (end-September 25), Hologic recorded revenues of $1.317 billion, down 2.3% compared with $1.347 billion in sales in the fourth quarter of 2020. The company's net income also fell, from $493.6 million in 2020 to $328.8 million in 2021.

Hologic saw revenue in its diagnostics business of $836.8 million, down 10.9% compared with sales of $939 million in the fourth quarter of 2020 due to lower sales of COVID-19 assays. Excluding revenues from COVID-19 tests, diagnostics sales grew 5.1% after currency adjustment.

The company's breast health division posted revenue increases of 15.6%, at $334.2 million compared with 2020's $289.2 million.

Going forward into 2022, the company expects to report annual revenue of $3.75 to $4 billion, it said.

Hologic launches multiplex COVID/flu assay
Hologic's Aptima SARS-CoV-2/flu assay is now commercially available in North America and Europe for the simultaneous detection and differentiation of...
How AI for cervical cancer can help achieve healthcare equity
Despite cervical cancer being among the most treatable forms of cancer, it continues to kill hundreds of thousands of women globally each year, especially...
Hologic launches on-demand molecular testing in Europe
Hologic has launched its Novodiag on-demand molecular test for infectious diseases and antibiotic resistance in Europe.
Hologic posts strong Q3 revenues
Hologic posted strong revenues for its fiscal third quarter. The company attributed the solid financial results in part to recovery from the COVID-19...

Copyright © 2021 LabPulse.com

Last Updated ls 11/2/2021 10:10:02 AM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current